AbbVie

Today at this year’s International Parkinson and Movement Disorder Society Congress, we're showcasing the Phase 3 clinical trial results in #ParkinsonsDisease. Learn more about our work in neuroscience: https://bit.ly/3N22RGL #MDS2024

At this year’s International Parkinson and Movement Disorder Society Congress, we’re presenting data from our expanding movement disorder portfolio, including #ParkinsonsDisease, spasticity and cervical dystonia. Join us at booth 501 to explore our novel research and learn more about our newly acquired portfolio from Cerevel Therapeutics at booth 302. #MDS2024 [Video description: On-screen text reads, “Join us at the International Congress of Parkinson’s Disease and Movement Disorders September 27-October 1, Philadelphia, PA. Sharing 17 abstracts supporting Parkinson's disease, cervical dystonia and spasticity.” Followed by dates and times of AbbVie Symposium and Cerevel Symposium.]

To discover new medicines, #scientists analyze vast and often disparate data to find the proverbial needle in a haystack. See how our scientists are leveraging #AI and data tools to help gain insights in minutes: https://bit.ly/3zCaW1I [Video description: On-screen text reads, “The human body generates massive amounts of data, which scientists rely on to help understand the root causes of diseases. But scientists alone would need a lifetime to analyze all this data. Instead they’re using AI and an industry-leading data platform to collate over 2 billion points of knowledge to deliver insights that can help us discover new medicines faster.”]

NEWS: Today we announced positive topline results from our pivotal Phase 3 trial for our investigational treatment in #ParkinsonsDisease. Learn more about the results: https://bit.ly/3BkCfht [Video description: On-screen text reads, “Neuroscience News."]

#LiverCancer is the sixth most common cancer worldwide, and approximately 20% of liver cancer diagnoses are caused by #HepatitisC. Learn more about #HCV’s global impact and how we can act now to help eliminate the disease by 2030 in POLITICO Studio: https://politi.co/3ZJRAlI [Video description: Interview with John Ward, Director, Global Coalition for Hepatitis Elimination. On-screen text reads, “More than 800,000 people worldwide are diagnosed with liver cancer each year. We estimate that by 2030, if we achieve hepatitis C elimination goals, we can avert over two million deaths from liver disease, including liver cancer. Join us as we work to help eliminate Hepatitis C.”]

Through #migraine research, we’re dedicated to growing a deep understanding of the mental, physical and socio-economic impacts of this disease on patients. During #MigraineAwarenessWeek, learn more about the burden of migraine from our own employees: https://bit.ly/4gBOMgK [Video description: AbbVie employees share their experiences living with migraine. On-screen text reads, “Some AbbVie employees are migraine patients too.”]

NEWS: New post-hoc data of #atopicdermatitis stratified by the severity of disease in the head and neck region was presented today at the #EADVCongress. Learn more about how we’re striving to meet patient needs through new research and data in immune-mediated skin diseases: https://bit.ly/47Cf6mR [Video description: On-screen text reads, “Immunology News.”]

AbbVie in Australia is proud to support the Crohn’s & Colitis Australia Live Fearless Challenge for the sixth consecutive year. Fundraising efforts support CCA’s work in education, advocacy and research with the aim of improving outcomes for people affected by inflammatory bowel disease. Learn more about the month-long fitness challenge here: https://bit.ly/4ewOfL4. Crohn’s & Colitis Australia #livefearlesschallenge #IBD #community

#DrugDiscovery is like a puzzle - and our #MachineLearning team, led by Abhishek Pandey, is finding new ways to solve it. Watch the full conversation in Piecing It Together, a series featuring employees across our organization and how they’re solving challenges and making an impact: https://bit.ly/3XYWIS4 #AI [Video description: Two AbbVie employees sitting at a table, playing a game involving stacking blocks, while discussing machine learning in drug discovery.]

Tune into this year’s #EADVCongress to see how we’re striving to meet patient needs through new research and data in immune-mediated skin diseases: https://bit.ly/3zksYpf [Video description: Animation of people, a person speaking at a podium, and Amsterdam on a map. On-screen text reads, “EADV 2024 Looking ahead. 33 accepted abstracts across 5 immune-mediated skin diseases, atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, hidradenitis suppurativa, 6 oral presentations, 3 symposia. See you there!”]